---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-001849"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2024-01-11T23:59:59+00:00"
generated_at: "2026-06-07T00:24:34.792591+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics cuts FY24 revenue guidance to $320-325M; Q2 revenue $79.1M, Auryon sales up 12.9%

## Summary
- FY24 revenue guidance lowered to $320M-$325M from $328M-$333M; adjusted EPS loss widens to ($0.35)-($0.42) from ($0.28)-($0.34).
- Q2 FY24 pro forma revenue $79.1M, growth 2.7%; Med Tech +3.5%, Auryon sales $11.4M (+12.9% YoY).
- PRESERVE (NanoKnife) and APEX AV (AlphaVac PE) studies fully enrolled; FDA submission for PE planned early 2024.
- Cumulative Auryon sales exceeded $100M; CE Mark for Auryon and AlphaVac expected 1H 2024.
- Full-year adjusted EPS profitability expected in FY27; manufacturing restructuring to fully outsourced model initiated.

## SEC filing metadata
- accession: 0001140361-24-001849
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2024-01-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000114036124001849/0001140361-24-001849-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000114036124001849/ef20018682_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-001849
- JSON: https://secwatch.observer/filing/0001140361-24-001849.json
- Plain text: https://secwatch.observer/filing/0001140361-24-001849.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.